Role of IL-6 in neuroendocrine differentiation and chemosensitivity of non-small cell lung cancer

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 289, Issue 3 33-3, 2005, Pages

  Chang, Kuo Ting ^a,b   Huang, Chi Ying F ^a,b   Tsai, Chun Ming ^c,d   Chiu, Chao Hua ^c,d   Lok, Ying Yung ^c,d  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Interleukin 6

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; NEURON SPECIFIC ENOLASE;

ARTICLE; CELL COUNT; CELL GROWTH; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; CULTURE MEDIUM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG NON SMALL CELL CANCER; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL COUNT; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TUMOR; CISPLATIN; COLORING AGENTS; DOWN-REGULATION; ETOPOSIDE; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; NEUROSECRETORY SYSTEMS; PHOSPHOPYRUVATE HYDRATASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, INTERLEUKIN-6; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES;

EID: 23944489286     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.00033.2005     Document Type: Article

References (45)

1. Abbona G, Papotti M, Viberti L, Macri L, Stella A, and Bussolati G. Chromogranin A gene expression in non-small cell lung carcinomas. J Pathol 186: 151-156, 1998.
2. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate 39: 135-148, 1999.
3. Adler HL, McCurdy MA, Rattan MW, Timme TL, Scardino PT, and Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Ural 161: 182-187, 1999.
4. Barnes MN, Deshane JS, Siegal GP, Alvarez RD, and Curiel DT. Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity. Clin Cancer Res 2: 1089-1095, 1996.
5. Bernick PE, Klimstra DS, Shia J, Minsky B, Saltz L, Shi W, Thaler H, Guillem J, Paty P, Cohen AM, and Wong WD. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum 47: 163-169, 2004.
6. Bihl M, Tamm M, Nauck M, Wieland H, Perruchoud AP, and Roth M. Proliferation of human non-small cell lung cancer cell lines: role of interleukin-6. Am J Respir Cell Mol Biol 19: 606-612, 1998.
7. Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travail S, and D'Alessandro N. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 85: 134-144, 1999.
8. Carles J, Rosell R, Ariza A, Pellicer I, Sanchez JJ, Fernandez-Vasalo G, Abad A, and Barnadas A. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer 10: 209-219, 1993.
9. Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng KS, and Huang FCY. IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 289: L446-L453, 2005.
10. De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A, and Catalane G. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 5: 649-652, 1998.
11. Gajra A, Tatum AH, Newman N, Gamble GP, Lichtenstein S, Rooney MT, and Graziano SL. The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer. Lung Cancer 36: 159-165, 2002.
12. Gazdar AF, Kadoyama C, Venzon D, Park JG, Tsai CM, Linnoila RI, Mulshine JL, Ihde DC, and Giaccone G. Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. J Natl Cancer Inst Monogr 13: 191-196, 1992.
13. Giri D, Ozen M, and Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159: 2159-2165, 2001.
14. Graziano SL, Kern JA, Herndon JE, Tatum A, Brisson ML, Memoli V, Sugarbaker D, Skarin AT, Kreisman H, and Green MR. Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a cancer and leukemia group B study. Lung Cancer 21: 203-211, 1998.
15. Graziano SL, Mazid R, Newman N, Tatum A, Oler A, Mortimer JA, Gullo JJ, DiFino SM, and Scalzo AJ. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small cell lung cancer. J Clin Oncol 7: 1398-1406, 1989.
16. Graziano SL, Tatum A, Herndon JE II, Box J, Memoli V, Green MR, and Kern JA. Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a cancer and leukemia group B study. Lung Cancer 33: 115-123, 2001.
17. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, and Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1-20, 2003.
18. Jee SH, Shen SC, Chiu HC, Tsai WL, and Kuo ML. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 20: 198-208, 2001.
19. Johnson BE. Biologic and molecular prognostic factors-impact on treatment of patients with non-small cell lung cancer. Chest 107: 287S-290S, 1995.
20. Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L, and Robinson RA. p185neu Expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50: 5184-5187, 1990.
21. Kim J, Adam RM, and Freeman MR. Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. Cancer Res 62: 1549-1554, 2002.
22. Kinoshita T, Ito H, and Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 85: 2526-2531, 1999.
23. Kloppel G. [Neuroendocrine tumors of the gastrointestinal tract]. Pathologe 24: 287-296, 2003.
24. Kulpa J, Wojcik E, Reinfuss M, and Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 48: 1931-1937, 2002.
25. Lee JD, Sievers TM, Skotzko M, Chandler CF, Morion DL, McBride WH, and Economou JS. Interleukin-6 production by human melanoma cell lines. Lymphokine Cytokine Res 11: 161-166, 1992.
26. Linnoila RI. Spectrum of neuroendocrine differentiation in lung cancer cell lines featured by cytomorphology, markers, and their corresponding tumors. J Cell Biochem Suppl 24: 92-106, 1996.
27. Malik S and Waxman J. Cytokines and cancer. Br Med J 305: 265-267, 1992.
28. Marangos PJ and Schmechel DE. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci 10: 269-295, 1987.
29. Miyamoto Y, Hosotani R, Doi R, Wada M, Ida J, Tsuji S, Kawaguchi M, Nakajima S, Kobayashi H, Masui T, and Imamura M. Interleukin-6 inhibits radiation induced apoptosis in pancreatic cancer cells. Anticancer Res 21: 2449-2456, 2001.
30. Naka T, Nishimoto N, and Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 4, Suppl 3: S233-S242, 2002.
31. Nakanishi Y, Cuttitta F, Kasprzyk PG, Avis I, Steinberg SM, Gazdar AF, and Mulshine JL. Growth factor effects on small cell lung cancer cells using a colorimetric assay: can a transferrin-like factor mediate autocrine growth? Exp Cell Biol 56: 74-85, 1988.
32. Pujol JL, Boher JM, Grenier J, and Quantin X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 31: 221-231, 2001.
33. Qiu Y, Ravi L, and Kung HJ. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 393: 83-85, 1998.
34. Qiu Y, Robinson D, Pretlow TG, and Kung HJ. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci USA 95: 3644-3649, 1998.
35. Ruckdeschel JC, Linnoila RI, and Mulshine JL. The impact of neuroendocrine and epithelial differentiation on response and survival in lung cancer: the ECOG experience. Proc Am Soc Clin Oncol 10: 248, 1991.
36. Schleusener JT, Tazelaar HD, Jung SH, Cha SS, Cera PJ, Myers JL, Creagan ET, Goldberg RM, and Marschke RF Jr. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. Cancer 77: 1284-1291, 1996.
37. Skov BG, Sorensen JB, Hirsch FR, Larsson LI, and Hansen HH. Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. Ann Oncol 2: 355-360, 1991.
38. Spiotto MT and Chung TD. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 42: 186-195, 2000.
39. Strassmann G, Fong M, Kenney JS, and Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89: 1681-1684, 1992.
40. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, and Sugimachi K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 27: 1372-1375, 1991.
41. Tsai CM, Chang KT, Perng RP, Mitsudomi T, Chen MH, Kadoyama C, and Gazdar AF. Correlation of intrinsic chemoresistance of non-small cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 85: 897-901, 1993.
42. Veldhuis GJ, Willemse PH, Sleijfer DT, van der Graaf WT, Groen HJ, Limburg PC, Mulder NH, and de Vries EG. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small cell lung cancer. J Clin Oncol 13: 2585-2593, 1995.
43. Wei LH, Kuo ML, Chen CA, Chou CH, Cheng WF, Chang MC, Su JL, and Hsieh CY. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mc1-1 through a PI 3-K/Akt pathway. Oncogene 20: 5799-5809, 2001.
44. Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T, and Ogura T. Serum levels of interleukin 6 in patients with long cancer. Br J Cancer 71: 1095-1098, 1995.
45. Zekioglu O, Erhan Y, Ciris M, and Bayramoglu H. Neuroendocrine differentiated carcinomas of the breast: a distinct entity. Breast 12: 251-257, 2003.